NCT01233648已完成4 期
Resync-AF (Rate vs Rhythm Control in AF Patients With CRT-D)
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 52
- 试验地点
- 2
- 主要终点
- AF burden
研究概览
简要总结
This study is being done to find out if controlling rate or controlling rhythm is better for heart failure patients who also have AF. Patients with AF who are receiving a CRT-D device and AV node ablation as part of their clinical care will be followed for one year. One group will have their heart rate controlled by the ICD and AVN ablation alone and the second group will be treated with the ICD, AVN ablation and standard medical therapies to restore the heart's normal rhythm. The study doctors will compare the information collected from all of the subjects in this study to see if treating rate or treating rhythm is better in patients with heart failure and AF, resulting in a better quality of life.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Having persistent AF, defined as AF that does not self terminate for at least 24 consecutive hours.
- •In AF upon entry into the operating room for CRT-D implantation and AV node ablation.
- •Being on a stable dosage of an ACE inhibitor or ARB for at least 1 month preceding implant
- •Being on a Beta-blocker for at least 3 months preceding implant and a stable dosage within 1 month of implant
- •Not taking or able to be taken off all type I/III antiarrhythmic medications.
- •Taking Coumadin so as to maintain an INR of between 2 and
- •A Class I or IIa ICD indication
- •NYHA Class III/IV within 1 month of baseline
- •Intrinsic QRS duration ≥ 130 ms within 1 month prior to baseline
- •Left ventricular ejection fraction ≤ 35% (method per physician discretion) within 1 month prior to baseline
- •Left ventricular end diastolic dimension (LVEDD) ≥ 55 mm (method per physician discretion) within 1 months prior to baseline
- •Willing to provide written informed consent
- •Are expected to survive for 6 month of study participation
- •Able to tolerate an urgent thoracotomy
- •Able to tolerate < 1 mg dexamethasone sodium phosphate (steroid)
排除标准
- •Having self-terminating or interminable AF
- •Having unstable angina, or having experienced an acute myocardial infarction (MI) or received coronary artery revascularization (CABG) or coronary angioplasty (PTCA) within the past 1 month
- •Post-heart transplant (patients on heart transplant list for the first time are not excluded)
- •Having mechanical right heart valve
- •Having an existing CRT or atrial therapy device(s)
- •Being enrolled in any concurrent drug and/or device study which would confound the results of this trial
- •Having primary valvular disease and indicated for valve repair or replacement
- •Having a previous AV node ablation
- •Being on a Type I or Type III anti-arrhythmic medication for the treatment of ventricular tachyarrhythmias
- •Women who are pregnant or with child bearing potential and who are not on a reliable form of birth control
结局指标
主要结局
AF burden
时间窗: 1 year
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
Prospective Multicenter Randomized and Controlled Study Evaluating the Benefit of Early Pulmonary Vein Isolation Compared to Usual Treatment in Patients Aged Over 75 Years and Presenting With Atrial FibrillationAtrial FibrillationNCT06322017Nantes University Hospital294
招募中
不适用
Rate or Rhythm Control in CRT: the RHYTHMIC StudyHeart FailureAtrial FibrillationNCT04664686Guy's and St Thomas' NHS Foundation Trust70
招募中
不适用
Rate Control Efficacy in Atrial Fibrillation With Rheumatic Mitral Stenosis: Lenient vs Strict Rate Control StrategiesRheumatic Mitral StenosisArrhythmias, CardiacAtrial FibrillationNCT06409533University of Brawijaya100
Unknown
4 期
Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot StudyHeart FailureAtrial FibrillationNCT01850277National Institute of Cardiology, Warsaw, Poland60
已完成
不适用
Mascot Study: Management of Atrial Fibrillation (AF) Suppression in AF-Heart Failure (HF) COmorbidity TherapyVentricular DysfunctionHeart FailureAtrial FibrillationNCT00187252Abbott Medical Devices380